These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 32979020)

  • 41. The use of nonselective beta blockers is a risk factor for portal vein thrombosis in cirrhotic patients.
    Zampino R; Lebano R; Coppola N; Macera M; Grandone A; Rinaldi L; De Sio I; Tufano A; Stornaiuolo G; Adinolfi LE; Durante-Mangoni E; Battista GG; Niglio A
    Saudi J Gastroenterol; 2018; 24(1):25-29. PubMed ID: 29451181
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The MELD score in advanced liver disease: association with clinical portal hypertension and mortality.
    Saab S; Landaverde C; Ibrahim AB; Durazo F; Han S; Yersiz H; Farmer DG; Ghobrial RM; Goldstein LI; Tong MJ; Busuttil RW
    Exp Clin Transplant; 2006 Jun; 4(1):395-9. PubMed ID: 16827633
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Treatment of Oesophageal Varices in Liver Cirrhosis.
    Sauerbruch T; Wong F
    Digestion; 2019; 99(4):261-266. PubMed ID: 30212817
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Use of Nonselective β-Blockers in Patients With End-Stage Liver Disease and Select Complications.
    Bultas AC; Teshome B; Richter SK; Schafers S; Cooke E; Call WB
    Ann Pharmacother; 2020 Jun; 54(6):583-593. PubMed ID: 31810371
    [No Abstract]   [Full Text] [Related]  

  • 45. Amelioration of systemic inflammation in advanced chronic liver disease upon beta-blocker therapy translates into improved clinical outcomes.
    Jachs M; Hartl L; Schaufler D; Desbalmes C; Simbrunner B; Eigenbauer E; Bauer DJM; Paternostro R; Schwabl P; Scheiner B; Bucsics T; Stättermayer AF; Pinter M; Trauner M; Mandorfer M; Reiberger T
    Gut; 2021 Sep; 70(9):1758-1767. PubMed ID: 33199442
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Beta adrenergic blockade and decompensated cirrhosis.
    Reiberger T; Mandorfer M
    J Hepatol; 2017 Apr; 66(4):849-859. PubMed ID: 27864004
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Non-invasive response prediction in prophylactic carvedilol therapy for cirrhotic patients with esophageal varices.
    Kim HY; So YH; Kim W; Ahn DW; Jung YJ; Woo H; Kim D; Kim MY; Baik SK
    J Hepatol; 2019 Mar; 70(3):412-422. PubMed ID: 30389550
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Identifying optimal candidates for early TIPS among patients with cirrhosis and acute variceal bleeding: a multicentre observational study.
    Lv Y; Zuo L; Zhu X; Zhao J; Xue H; Jiang Z; Zhuge Y; Zhang C; Sun J; Ding P; Ren W; Li Y; Zhang K; Zhang W; He C; Zhong J; Peng Q; Ma F; Luo J; Zhang M; Wang G; Sun M; Dong J; Bai W; Guo W; Wang Q; Yuan X; Wang Z; Yu T; Luo B; Li X; Yuan J; Han N; Zhu Y; Niu J; Li K; Yin Z; Nie Y; Fan D; Han G
    Gut; 2019 Jul; 68(7):1297-1310. PubMed ID: 30415233
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Minimal hepatic encephalopathy and critical flicker frequency are associated with survival of patients with cirrhosis.
    Ampuero J; Simón M; Montoliú C; Jover R; Serra MÁ; Córdoba J; Romero-Gómez M
    Gastroenterology; 2015 Nov; 149(6):1483-9. PubMed ID: 26299413
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Statin use in patients with cirrhosis: a retrospective cohort study.
    Kumar S; Grace ND; Qamar AA
    Dig Dis Sci; 2014 Aug; 59(8):1958-65. PubMed ID: 24838495
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Predicting response to non-selective beta-blockers with liver-spleen stiffness and heart rate in patients with liver cirrhosis and high-risk varices.
    Giuffrè M; Dupont J; Visintin A; Masutti F; Monica F; You K; Shung DL; Crocè LS;
    Hepatol Int; 2024 Apr; ():. PubMed ID: 38664292
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Association Between Portosystemic Shunts and Increased Complications and Mortality in Patients With Cirrhosis.
    Simón-Talero M; Roccarina D; Martínez J; Lampichler K; Baiges A; Low G; Llop E; Praktiknjo M; Maurer MH; Zipprich A; Triolo M; Vangrinsven G; Garcia-Martinez R; Dam A; Majumdar A; Picón C; Toth D; Darnell A; Abraldes JG; Lopez M; Kukuk G; Krag A; Bañares R; Laleman W; La Mura V; Ripoll C; Berzigotti A; Trebicka J; Calleja JL; Tandon P; Hernandez-Gea V; Reiberger T; Albillos A; Tsochatzis EA; Augustin S; Genescà J;
    Gastroenterology; 2018 May; 154(6):1694-1705.e4. PubMed ID: 29360462
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Combined therapies versus monotherapies for the first variceal bleeding in patients with high-risk varices: a meta-analysis of randomized controlled trials.
    Bai M; Qi X; Yang M; Han G; Fan D
    J Gastroenterol Hepatol; 2014 Mar; 29(3):442-52. PubMed ID: 24118091
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Non-selective betablocker therapy decreases intestinal permeability and serum levels of LBP and IL-6 in patients with cirrhosis.
    Reiberger T; Ferlitsch A; Payer BA; Mandorfer M; Heinisch BB; Hayden H; Lammert F; Trauner M; Peck-Radosavljevic M; Vogelsang H;
    J Hepatol; 2013 May; 58(5):911-21. PubMed ID: 23262249
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Non-Selective Beta-Blockers Decrease Infection, Acute Kidney Injury Episodes, and Ameliorate Sarcopenic Changes in Patients with Cirrhosis: A Propensity-Score Matching Tertiary-Center Cohort Study.
    Li TH; Liu CW; Huang CC; Tsai YL; Huang SF; Yang YY; Tsai CY; Hou MC; Lin HC
    J Clin Med; 2021 May; 10(11):. PubMed ID: 34064207
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Aetiology of cirrhosis of the liver has an impact on survival predicted by the Model of End-stage Liver Disease score.
    Angermayr B; Luca A; König F; Bertolini G; Ploner M; Gridelli B; Ulbrich G; Reiberger T; Bosch J; Peck-Radosavljevic M
    Eur J Clin Invest; 2009 Jan; 39(1):65-71. PubMed ID: 19087131
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Nonselective β-Blockers and Survival in Patients With Cirrhosis and Ascites: A Systematic Review and Meta-analysis.
    Chirapongsathorn S; Valentin N; Alahdab F; Krittanawong C; Erwin PJ; Murad MH; Kamath PS
    Clin Gastroenterol Hepatol; 2016 Aug; 14(8):1096-1104.e9. PubMed ID: 26829026
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Decreasing von Willebrand Factor Levels Upon Nonselective Beta Blocker Therapy Indicate a Decreased Risk of Further Decompensation, Acute-on-chronic Liver Failure, and Death.
    Jachs M; Hartl L; Simbrunner B; Bauer D; Paternostro R; Scheiner B; Schwabl P; Stättermayer AF; Pinter M; Eigenbauer E; Quehenberger P; Trauner M; Reiberger T; Mandorfer M
    Clin Gastroenterol Hepatol; 2022 Jun; 20(6):1362-1373.e6. PubMed ID: 34256145
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Safety of Nonselective Beta-Blockers in Decompensated Liver Cirrhosis and Their Role in Inducing Hepatorenal Syndrome.
    Qaqish F; Dimachkie R; Sasso R; Loeffler J; Hasan M; Deghani S; Abou Yassine A; Deeb L
    Cureus; 2024 Apr; 16(4):e58296. PubMed ID: 38752039
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Transjugular Intrahepatic Porto-Systemic Shunt in Patients with Liver Cirrhosis and Model for End-Stage Liver Disease ≥15.
    Ascha M; Hanouneh M; S Ascha M; Zein NN; Sands M; Lopez R; Hanouneh IA
    Dig Dis Sci; 2017 Feb; 62(2):534-542. PubMed ID: 27154510
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.